26.69
-1.19 (-4.27%)
| 前收盘价格 | 27.88 |
| 收盘价格 | 28.00 |
| 成交量 | 1,045,372 |
| 平均成交量 (3个月) | 757,477 |
| 市值 | 1,326,724,096 |
| 价格/销量 (P/S) | 501.65 |
| 股市价格/股市净资产 (P/B) | 4.02 |
| 52周波幅 | |
| 利润日期 | 6 May 2026 |
| 营业毛利率 | 31.01% |
| 营业利益率 (TTM) | 29.97% |
| 稀释每股收益 (EPS TTM) | 0.070 |
| 总债务/股东权益 (D/E MRQ) | 8.84% |
| 流动比率 (MRQ) | 16.10 |
| 营业现金流 (OCF TTM) | 69.88 M |
| 杠杆自由现金流 (LFCF TTM) | 52.09 M |
| 资产报酬率 (ROA TTM) | 23.07% |
| 股东权益报酬率 (ROE TTM) | 34.38% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Maze Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | -2.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -5.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.60 |
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 5.91% |
| 机构持股比例 | 92.25% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Trv Gp Iv, Llc | 31 Dec 2025 | 4,473,958 |
| Arch Venture Management, Llc | 31 Dec 2025 | 4,120,053 |
| A16z Capital Management, L.L.C. | 31 Dec 2025 | 1,702,225 |
| General Catalyst Group Management, Llc | 31 Dec 2025 | 1,035,910 |
| Trv Gp V, Llc | 31 Dec 2025 | 950,800 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 97.00 (Mizuho, 263.43%) | 购买 |
| 中 | 58.00 (117.31%) | |
| 低 | 46.00 (BTIG, 72.35%) | 购买 |
| 平均值 | 67.00 (151.03%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 47.53 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Mizuho | 10 Mar 2026 | 97.00 (263.43%) | 购买 | 51.06 |
| BTIG | 09 Mar 2026 | 46.00 (72.35%) | 购买 | 45.06 |
| 16 Jan 2026 | 46.00 (72.35%) | 购买 | 40.77 | |
| Guggenheim | 04 Mar 2026 | 58.00 (117.31%) | 购买 | 46.48 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BACHRODT AMY | - | 29.05 | -2,500 | -72,625 |
| BERNSTEIN HAROLD | - | 29.05 | -15,000 | -435,750 |
| 累积净数量 | -17,500 | |||
| 累积净值 ($) | -508,375 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 29.05 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| BACHRODT AMY | 职员 | 01 Apr 2026 | 自动卖出 (-) | 2,500 | 29.05 | 72,625 |
| BACHRODT AMY | 职员 | 01 Apr 2026 | 执行期权 | 2,500 | - | - |
| BERNSTEIN HAROLD | 职员 | 01 Apr 2026 | 自动卖出 (-) | 15,000 | 29.05 | 435,750 |
| BERNSTEIN HAROLD | 职员 | 01 Apr 2026 | 执行期权 | 15,000 | - | - |
| 日期 | 类型 | 细节 |
|---|---|---|
| 04 Feb 2026 | 公告 | Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合